scholarly journals Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer

2009 ◽  
Vol 121 (1) ◽  
pp. 35-40 ◽  
Author(s):  
Einar Gudlaugsson ◽  
Ivar Skaland ◽  
Emiel A. M. Janssen ◽  
Paul J. van Diest ◽  
Feja J. Voorhorst ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Lymph Node ◽  
Invasive Breast Cancer ◽  
Node Negative

The relationship between lymph node metastases and DNA-ploidy status as prognostic factors in invasive breast cancer

Surgery Today ◽  
1992 ◽  
Vol 22 (3) ◽  
pp. 213-220 ◽  
Author(s):  
Masakuni Noguchi ◽  
Nagayoshi Ohta ◽  
Naohiro Koyasaki ◽  
Takao Taniya ◽  
Itsuo Miyazaki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Lymph Node ◽  
Invasive Breast Cancer ◽  
Lymph Node Metastases ◽  
Dna Ploidy ◽  
Node Metastases ◽  
The Relationship ◽  
Ploidy Status

scholarly journals Correlation between mammographic and sonographic findings and prognostic factors in patients with node-negative invasive breast cancer

2011 ◽  
Vol 84 (997) ◽  
pp. 19-30 ◽  
Author(s):  
H J Shin ◽  
H H Kim ◽  
M O Huh ◽  
M J Kim ◽  
A Yi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Invasive Breast Cancer ◽  
Node Negative

Can Features Evaluated in the Routine Pathologic Assessment of Lymph Node–Negative Estrogen Receptor–Positive Stage I or II Invasive Breast Cancer Be Used to Predict the Oncotype DX Recurrence Score?

2010 ◽  
Vol 134 (11) ◽  
pp. 1697-1701
Author(s):  
Jena Auerbach ◽  
Mimi Kim ◽  
Susan Fineberg
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Lymph Node ◽  
Invasive Breast Cancer ◽  
Recurrence Score ◽  
Mitotic Count ◽  
Oncotype Dx ◽  
Node Negative ◽  
Estrogen Receptor Positive ◽  
Pathologic Assessment

Abstract Context.—Oncotype DX is a multigene reverse transcription–polymerase chain reaction assay used to quantify recurrence risk in patients with stage I or II estrogen receptor–positive, lymph node–negative invasive breast cancer. The results are reported as a Recurrence Score (RS). The 16 cancer genes evaluated include a proliferation set, hormone receptor set, and HER2 set. The activity of these genes is addressed by pathologic assessment of breast cancers. Objective.—To determine if factors evaluated in pathologic evaluation of breast cancer could be used to predict Oncotype DX results. Design.—We studied 138 cases of invasive breast cancer for which Oncotype DX results and pathology data were available. Grading was performed by using Nottingham grading system. For hormone receptor immunostaining, 10% nuclear staining was considered a positive result. Results.—Oncotype DX RS was low in 81 cases, intermediate in 44 cases, and high in 13 cases. All 6 cases with both a negative progesterone receptor (PR) and a mitotic count score of 3 had a high RS. All 12 cases with both a negative PR and a mitotic count score greater than 1 had either an intermediate or high RS. Although Nottingham grade, PR status, mitotic count score, tumor size, and nuclear grade were each significantly associated with RS, in bivariate analyses the only variables that remained independently predictive of an intermediate or high RS score in a multivariate logistic regression model were negative PR and mitotic count score greater than 1. Conclusions.—Our study suggests that a mitotic count score greater than 1 combined with a negative PR result, as determined by pathologic assessment, could serve as a marker for an intermediate or high Oncotype DX RS.

Prognostic factors and natural history in lymph node-negative breast cancer patients

1992 ◽  
Vol 21 (2) ◽  
pp. 101-109 ◽  
Author(s):  
Rodrigo Arriagada ◽  
Lars Erik Rutqvist ◽  
Lambert Skoog ◽  
Hemming Johansson ◽  
Andrew Kramar
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Lymph Node ◽  
Natural History ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer

scholarly journals Prognostic Factors in Axillary Lymph Node Negative Breast Cancer

2004 ◽  
Vol 7 (2) ◽  
pp. 111 ◽  
Author(s):  
Se Ho Park ◽  
Seung Il Kim ◽  
Byeong Woo Park ◽  
Kyong Sik Lee
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Lymph Node ◽  
Axillary Lymph Node ◽  
Axillary Lymph ◽  
Node Negative ◽  
Node Negative Breast Cancer

HER2 status of patients with invasive breast cancer in a population at a single UK centre: Correlation with tumor characteristics

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 11094-11094
Author(s):  
B. Saleh ◽  
S. Jader ◽  
J. Singer ◽  
S. Jenkins ◽  
H. Bradpiece ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Invasive Breast Cancer ◽  
Age Groups ◽  
Her2 Status ◽  
Lymph Node Status ◽  
Her2 Overexpression ◽  
Her2 Expression ◽  
Her2 Positive ◽  
Node Negative

11094 Background: The human epidermal growth factor receptor 2 (HER2) overexpression, has been correlated with higher histological grade, increased tumour size, positive lymph node status, and negative or lower oestrogen receptor (ER) expression. Our aim was to look at the association between HER2 status, patient age and tumour histopathologic characteristics. Methods: We analysed retrospectively 735 cases of invasive breast cancer treated between the years 2000 and 2004. HER2 was measured by immunohistochemistry (IHC) and all IHC 2+ tumours were also tested by fluorescent in situ hybridisation (FISH). All information was collected from pathology reports in patient case records. Results: A total of 143 (19.5%) tumours were HER2 positive (120 IHC 3+ and 23 IHC 2+/FISH+). Of the 66 tumours that were IHC 2+, 23 (34.8%) were FISH-positive. The age of most patients (75.8%) was over 50 years but there was a higher incidence (28%) of HER2 overexpresion in the 40–49 age group compared to all other age groups, the incidence of HER2 overexpression was still at least 17–18% in all age groups, including patients aged =70 years. Although, a high proportion of patients (62.2%) had tumours less than 2 cm in size, comparison of tumours less than 2 cm with those greater than 2 cm showed no predictive effect of size on HER2 expression. Over half of the patients had lymph node-negative disease (55.2%) and despite some association of HER2 expression with lymph node involvement (odds ratio of 1.23 for comparison of lymph node-positive versus negative), 19% of lymph node-negative tumours overexpressed HER2. Most tumours were high grade (32.8% grade 3, 44.1% grade 2 ) and although the proportion of HER2 overexpression increased with increasing tumour grade, some grade 1 tumours still overexpressed HER2. A higher proportion (28%) of ER-negative tumours was HER2 positive compared to ER-positive tumours (18%); however, co-expression of HER2 and ER occurred in 14% (105/735) of all primary cancers. Conclusions: In conclusion, it is not possible to predict which patients will be HER2 positive. Therefore, it is essential that HER2 status should be determined in all patients with invasive breast cancer to allow a decision on the use of trastuzumab and guide the choice of chemotherapy. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document